Welcome to the South East Asia Breast Cancer Symposium 2016

Breast cancer is the most common cancer and a leading cause of mortality in women in South East Asia. In recent years, health care in general, and particularly for women has received significant attention. The South East Asia Breast Cancer Symposium (SEABCS) provides a forum in which global and regional experts in the field of breast cancer will present and discuss advanced methods in: diagnosis, surgery, radiation and chemotherapy for both early and late stage interventions.

SEABCS 2016 will also focus on improving capacity for breast cancer prevention as well as presenting the latest information and innovations surrounding diagnosis and treatment of breast cancer for doctors in the region...

Important dates

Instructions and online submission available on website : http://seabcs.org/

Abstract Submission Deadline: May 01st, 2016

Early Bird Registration Deadline: March 25th,2016

Registration Deadline: June 1th,2016

Call for Exhibitor, Call for Sponsors Deadline: April 15th, 2016

Who Should Attend

Oncologists - Radiologists - Pathologists - Pharmacists - Nurses - General Practitioners - All Surgeons - Allied Health Professionals
Breast cancer survivors meet with experts in June 26, 2006


President of Breast Cancer Society of Hue

President of Breast Surgery International

President of Global Focus on Cancer

Medical Officer
Management of Noncommunicable Diseases
World Health Organization

Hue University of Medicine and Pharmacy

Chief Executive Cancer Research Malaysia (formerly known as Cancer Research Initiatives Foundation (CARIF))

Professor, Dept of Endocrine & Breast Surgery, SGPGIMS, Lucknow- 226014, INDIA
Phone: (522) 2494160, 9415403141
Profile: http://www.sgpgibreasthealth.org/ProfileDrGaurav
Email: gaurav@sgpgi.ac.in ,  gauravbsi@gmail.com

Chief surgeon, Jorvi Hospital Unit, Department of Plastic Surgery, Helsinki University Central Hospital Private practitioner Helsinki Breast and Melanoma Center, Hospital Laser Tilkka

Acting Head, Department of Pathology, University of Manitoba
Medical Director of Anatomical Pathology, Diagnostic Services Manitoba, Canada

Consultant Plastic Surgeon
Southmead Hospital, Bristol ,BS16 1LE, England

The Jill Bennett Professor of Breast Medical Oncology at University of Washington School of Medicine,
Director of Breast Medical Oncology at the Seattle Cancer Care Alliance

Iscurrently Lecturer of the Department of Oncology at the Ho Chi Minh City University of Medicine and Pharmacy (UMP) and Consultant of the Department of Radiation Therapy at the HCM City OncologyHospital.
Vice-Rector, Research and International Relations, Hue University of Medicine and Pharmacy, Hue City, Vietnam.

Prince of Wales Hospital,Hong Kong
President, International Academy of Pathology, Hong Kong Division.
Vice President of Asia, International Academy of Pathology

Associate Professor of Pathology

Teacher at Hue College of Medicine and Pharmacy
Director of Global Strategy, Partnerships and Advocacy in the Division of Medical Oncology at the University of Washington in Seattle, Washington.
Head of oncology department, Hue university of medicine and pharmacy; chief of oncology department of Hue university hospital, vice-president of cancer society of Thua Thien Hue province.

MD(HK), MBBS (HK), MRCP (UK), FRCP(London), FHKCP (Med Onc), FHKAM (Medicine)


At the forum “War on Cancer” and "Asia Pacific Cancer Control Leadership Forum” held in Singapore on the 17th and 18th of March, the South-East Asia Breast Cancer Symposium 2016 (SEABCS 2016) was ranked as one of the events of the Global Cancer Research Events in 2016 by the National Cancer Institute of the United States.

Some cancers - such as breast cancer - have a greater inheritable risk than others. Now, researchers from the Washington University School of Medicine in St. Louis, MO, shed light on why this is, paving the way for better genetic tests for cancer risk.

  • New research that looks at the long-term effects of chemotherapy on breast cancer survivors finds it weakens parts of the immune system for at least 9 months after treatment. This could leave patients with insufficient resilience to common infections, such as pneumonia and tetanus, even if they were immunized previously, say the researchers.

  • Up to 19% of women are being incorrectly determined as having dense or non-dense breasts due to inconsistency in measuring breast density. Moreover, supplemental breast cancer screenings for women with dense breasts are greatly increasing the chance of both true and false positive results, says research published in the Annals of Internal Medicine.

  • New research published in PLoS Biology finds a link between a protein essential for milk production and an increased metastasis of breast cancer. The protein in question appears to aid breast cancer's advance through two separate pathways.

  • There is insufficient evidence to claim cancer screening saves lives, argue experts in a report published in The BMJ, who call for future studies to assess the impact of cancer screening on overall mortality rather than disease-specific mortality alone.

Held in and support by : Breast Cancer Society of Hue, Global Focus on Cancer, Breast Surgery International , Hue Central Hospital, Hue College of Medicine & Pharmacy